# US Gene Therapy Market > US Gene Therapy Market Research Report: Size, Share, Trend Analysis By Therapeutic Area (Oncology, Genetic Disorders, Infectious Diseases, Cardiovascular Diseases, Neurological Disorders), By Technology (Viral Vectors, CRISPR, Gene Editing, RNA Therapy, Non-Viral Methods), By Applications (Research, Clinical, Commercial) and By Route of Administration (Intravenous, Intramuscular, Intradermal, Intrathecal, Oral) - Growth Outlook & Industry Forecast 2025 To 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 17.84% - **2024:** $ 1,150 Million - **2025:** $ 1,355.16 Million - **2035:** $ 7,000 Million - **Key Players:** Novartis (CH), Gilead Sciences (US), Sangamo Therapeutics (US), Bluebird Bio (US), Spark Therapeutics (US), CRISPR Therapeutics (CH), Bristol-Myers Squibb (US), Roche (CH), AstraZeneca (GB), Regeneron Pharmaceuticals (US) **Report ID:** MRFR/Pharma/13087-HCR · **Pages:** 100 · **Author:** Rahul Gotadki & Garvit Vyas · **Last Updated:** April 06, 2026 **URL:** https://www.marketresearchfuture.com/reports/us-gene-therapy-market-14614 --- ## Market Summary ## **US Gene Therapy Market Overview** **As per MRFR analysis, the US Gene Therapy Market Size was estimated at 1.81 (USD Billion) in 2023. The US Gene Therapy Market Industry is expected to grow from 2.2 (USD Billion) in 2024 to 8.5 (USD Billion) by 2035. The US Gene Therapy Market CAGR (growth rate) is expected to be around 13.074% during the forecast period (2025 - 2035).** ### **Key US Gene Therapy Market Trends** The US gene therapy market is witnessing several key trends that are shaping its future. One significant trend is the increased regulatory support from government agencies like the FDA, which has streamlined the approval processes for gene therapies. This regulatory flexibility encourages innovation and promotes the development of new therapies to treat rare and complex diseases. Additionally, a growing number of collaborations between biotech companies and academic institutions in the US is fueling research and development efforts. This synergy helps in navigating the complex landscape of [gene therapy](../../../reports/gene-therapy-market-8399) while leveraging expertise and resources. Key market drivers for the US gene therapy market include the rising prevalence of genetic disorders and the demand for personalized medicine. As the population ages, the incidence of genetic diseases is expected to rise, which drives the need for effective treatments. The increasing public awareness of gene therapy and its potential benefits also propels market growth, alongside advancements in technologies like CRISPR and viral vector design that make gene editing more accessible and effective. ### **Opportunities and Future Trends** There are numerous opportunities to be explored within the US gene therapy market. Investment in infrastructure for manufacturing and distribution is essential to meet the growing demand for these therapies. Additionally, there is scope for expanding gene therapies into new therapeutic areas such as oncology, cardiology, and neurology, where existing treatment options may be limited. Trends in recent times reflect an increasing focus on developing all-in-one gene therapies that not only address the genetic cause of diseases but also provide a sustainable solution. The growing trend towards patient-centric approaches ensures that therapies are designed with input from patients, leading to improved outcomes and satisfaction. Thus, the US gene therapy market is on a path of dynamic growth, influenced by regulatory support, technological advancements, and increasing opportunities for expansion across diverse therapeutic areas. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ## **US Gene Therapy Market Drivers** ### **Increasing Genetic Disorders Prevalence** The rising prevalence of genetic disorders in the United States is a significant market driver for the US Gene Therapy Market Industry. Diseases such as cystic fibrosis, hemophilia, and muscular dystrophy collectively impact millions of Americans and are driving the demand for innovative therapies. According to the Centers for Disease Control and Prevention, approximately 1 in every 33 children in the US is born with a genetic disorder, which translates to about 120,000 births each year. Organizations like the National Institutes of Health are heavily investing in Research and Development for gene therapies aimed at these disorders. With advancements in technology and the increasing grants for therapeutic solutions, the market is anticipated to expand, as it directly addresses the urgent medical needs of this population. ### **Advancements in Gene Editing Technologies** Technological advancements in gene editing, particularly the development of CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats), play a crucial role in shaping the US Gene Therapy Market Industry. Research from the National Academy of Sciences indicates that CRISPR technology can target and edit specific genes, proving successful in eliminating genetic diseases in preclinical studies. The capability for precise modifications means that more therapies can enter the development stage, fueled by the intellectual property filings that have surged over the last few years, especially in areas like oncology. Prominent companies such as Editas Medicine are at the forefront, influencing the market trajectory and offering new possibilities for customized therapies. ### **Supportive Regulatory Environment** A supportive regulatory framework in the United States is essential for the growth of the US Gene Therapy Market Industry. The Food and Drug Administration has streamlined the approval processes for gene therapies, reflecting its commitment to expediting innovative treatments. Since the introduction of the Breakthrough Therapy Designation, over 20 gene therapies have received expedited review. This regulatory environment not only fosters innovation but also instills confidence in investors, propelling funding for Research and Development initiatives. The resulting commercialization of these therapies creates a unique opportunity, sectioning the US as a leader in gene therapy advancements. ### **Rising Investments in Biotech Sector** An increase in investments within the biopharmaceutical sector significantly drives the US Gene Therapy Market Industry. Venture capital funding in biotech firms focusing on gene therapies reached approximately USD 22 billion in 2020, according to the Biotechnology Innovation Organization. This financial influx supports the extensive Research and Development required for therapeutic innovations while spurring collaborations between established pharmaceutical companies and emerging biotech firms. With the rising number of partnerships, such as those seen with companies like Spark Therapeutics, the market is poised for accelerated growth, enabling the development of more effective and targeted gene therapies. ## **US Gene Therapy Market Segment Insights** ### **Gene Therapy Market Therapeutic Area Insights** The US Gene Therapy Market, particularly focusing on the Therapeutic Area segment, showcases a promising landscape driving innovation and growth. The intended applications of gene therapies cover various critical health areas, which include oncology, genetic disorders, infectious diseases, cardiovascular diseases, and neurological disorders. Among these, oncology has emerged as a forefront category, primarily due to the rising incidence of cancer, which leaves a significant impact on public health. Research demonstrates that gene therapies offer potential cures and targeted treatments for various cancers, thus paving a pathway for advanced and personalized treatment options that continue to attract substantial Research and Development funding. Genetic disorders represent another vital block within the Therapeutic Area of the US Gene Therapy Market. These conditions often have a hereditary base, affecting a notable portion of the population. Gene therapies target the underlying genetic causes of these disorders, promising a transformative approach across many hereditary diseases such as cystic fibrosis and hemophilia, which were once deemed difficult to manage effectively. The increasing recognition of the benefits of gene editing technologies has led healthcare professionals towards considering them as viable solutions for millions suffering from genetic defects. Infectious diseases have also gained significant attention in the realm of gene therapy. The COVID-19 pandemic has accelerated research and development efforts in this area, leading to innovative gene-based therapies aimed at combating various viral infections. There is a growing understanding that gene therapies can bolster the immune response and provide enduring protection against infectious agents, thus positioning this segment favorably for future advancements. Cardiovascular diseases represent a major health burden in the US, and gene therapy has begun to play a crucial role in addressing these challenges. With innovative approaches that aim to repair or regenerate cardiovascular tissues, the potential for cardiac gene therapies to improve outcomes for patients suffering from heart disease is considerable. The exploration of novel gene constructs and delivery methods puts cardiovascular applications at the forefront of gene therapy advancements. Lastly, neurological disorders encompass a range of debilitating conditions impacting cognitive and motor functions. There is an increasing focus on gene therapies that target conditions such as Alzheimer's disease, Parkinson's disease, and spinal muscular atrophy. The central nervous system presents unique challenges for gene delivery, yet ongoing advancements in technology are gradually unlocking possibilities for effective gene therapy solutions in this field. Overall, the Therapeutic Area segment within the US Gene Therapy Market holds substantial promise across diverse health conditions, with each area offering distinct opportunities for innovation. Growth is fueled by a confluence of factors including technological advancements, an increased understanding of gene editing mechanisms, and substantial investment from both the public and private sectors. This segment not only reflects the evolving landscape of modern medicine but also positions itself strategically within the healthcare framework, aiming to address some of the most pressing health challenges faced by the population today. Subsequently, the US Gene Therapy Market statistics indicate a robust framework for continued research, exploration, and integration of gene therapies across therapeutic landscapes. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ### **Gene Therapy Market Technology Insights** The Technology segment of the US Gene Therapy Market encompasses several innovative approaches driving advancements in genetic treatments. Viral vectors are widely utilized due to their efficiency in delivering therapeutic genes to target cells, making them a prominent choice in the industry. CRISPR technology represents a groundbreaking tool for precise gene editing, enabling researchers to modify the genome at specific locations, which is revolutionizing treatment strategies. Gene editing techniques are crucial for correcting genetic defects, thus holding exceptional potential in addressing inherited disorders. RNA therapy has gained attention for its capability to manipulate gene expression, offering promising avenues for treating various diseases. Additionally, Non-Viral Methods present an alternative to traditional vectors, utilizing physical and chemical methods for gene delivery, thus expanding the toolkit for gene therapy applications. Overall, the importance of these technologies in the US Gene Therapy Market cannot be overstated as they collectively contribute to minimizing disease burden and shaping the future landscape of therapeutic options available for patients. As the market continues to advance, these technological innovations will play a crucial role in furthering research and expanding treatment possibilities for a diverse range of conditions. ### **Gene Therapy Market Application Insights** The US Gene Therapy Market focuses significantly on applications ranging from Research to Clinical and Commercial use. This segment plays a pivotal role in advancing the understanding and treatment of genetic disorders and other diseases. Research applications facilitate breakthroughs by studying the mechanisms of gene therapies, which helps in identifying potential targets and refining techniques for therapeutic purposes. Clinical applications are vital as they implement these therapies in real-world scenarios, significantly impacting patient outcomes and offering innovative solutions for previously incurable conditions. Meanwhile, the Commercial segment is important as it translates successful therapeutic advancements into accessible treatments, ultimately enhancing the quality of healthcare in the US. As companies invest in these areas, the demand for novel gene therapies is rising, driven by the increasing prevalence of genetic disorders and advances in genetic engineering technologies. The US government has also shown strong support through initiatives aimed at expediting the approval processes for gene therapies, further fueling growth in the market. Overall, the application segment is crucial for the development and commercialization of gene therapies, which are expected to reshape the future of medicine. ### **Gene Therapy Market Route of Administration Insights** The Route of Administration segment within the US Gene Therapy Market plays a critical role in the delivery and effectiveness of therapeutic agents. As the market continues to evolve, various methods such as Intravenous, Intramuscular, Intradermal, Intrathecal, and Oral administration are being explored and utilized. Intravenous administration is often favored for its rapid deliverability, allowing for immediate therapeutic effects, while Intramuscular administration is significant for its ease of application and potential for sustained release of gene therapeutics. Intradermal routes are gaining attention due to their application in localized therapies, and the Intrathecal method is crucial for targeting the central nervous system, addressing conditions such as spinal muscular atrophy. Additionally, Oral administration offers a patient-friendly approach, increasing adherence and accessibility. Each of these methods plays a vital role in shaping treatment paradigms within the market, driven by ongoing innovations in drug delivery technologies. The growing demand for these administration routes reflects the broader trends of increased patient-centric care and personalized medicine, highlighting the dynamic landscape of the US Gene Therapy Market. ## **US Gene Therapy Market Key Players and Competitive Insights** The competitive landscape of the US Gene Therapy Market has gained significant attention due to its transformative potential in the treatment of various genetic disorders and diseases. Key players continue to emerge as research and development in gene therapies accelerate, supported by advancements in technology and scientific understanding. Companies within this sector focus on innovative approaches to gene modification, delivery systems, and regulatory strategies to establish their market presence. As the market evolves, collaborations with academic institutions, licensing agreements, and clinical trials remain crucial for companies looking to maintain or enhance their competitive edge. Additionally, increasing investments and favorable regulatory environments are encouraging new entrants and established pharmaceutical companies alike to invest heavily in gene therapy solutions, which enhances the overall competitiveness of the market. ### **Novartis** Novartis has established a strong foothold in the US Gene Therapy Market through its innovative product pipeline and strategic focus on developing breakthrough therapies for rare and chronic disorders. The company's expertise in cell and gene therapy has resulted in the successful commercialization of therapies that address critical unmet needs. Novartis boasts a deep understanding of regulatory pathways, which allows for faster development and delivery of therapies to the market. The company's robust financial resources enable significant investments in cutting-edge R&D, fostering an environment conducive to scientific advancement. Furthermore, Novartis maintains strategic partnerships, providing access to new technologies and expanding its portfolio of gene therapies, all of which contribute to its competitive position in the US market. ### **Verve Therapeutics** Verve Therapeutics is making significant strides in the US Gene Therapy Market by focusing on innovative approaches to treating genetic conditions, particularly cardiovascular diseases. The company's pioneering use of gene editing technology positions it uniquely within the industry, allowing for the development of therapies aimed at delivering long-term solutions through a one-time treatment approach. Verve Therapeutics is actively engaged in clinical trials that leverage its proprietary gene editing platform, showcasing its commitment to advancing healthcare solutions. The company has secured strategic collaborations and funding to enhance its R&D capabilities, further strengthening its market presence. The focus on collaboration extends towards potential mergers and acquisitions to access complementary technologies that align with its long-term goals of transforming the treatment landscape for inherited diseases in the US. Overall, Verve Therapeutics stands out for its innovative approach and strategic positioning in the evolving gene therapy sector. ### **Key Companies in the US Gene Therapy Market Include** ## **US Gene Therapy Market Industry Developments** Recent months have seen significant developments in the US Gene Therapy Market. Novartis received FDA approval for its gene therapy treatment Zolgensma for spinal muscular atrophy in July 2023, marking a pivotal moment in the treatment landscape. In September 2023, Gilead Sciences announced positive trial results for its gene therapy targeting hemophilia, showcasing advancements in therapeutic applications. Mergers and acquisitions maintain momentum, with Amgen acquiring Five Prime Therapeutics in May 2023 to augment its oncology portfolio, with implications for gene therapy advancements in cancer treatment. In terms of market valuation, companies like Bluebird Bio have experienced volatility, significantly impacting investor confidence and overall market stability. Current affairs indicate that regulatory frameworks are evolving to accommodate rapid advancements in gene therapy, driven by the FDA's commitment to expedite both approvals and patient access to innovative treatments, reflecting a broader trend in personalized medicine. Major happenings over the last few years underscore the urgency for continued investment in Research and Development, with CRISPR Therapeutics making strides in gene editing technology, further enhancing competitive dynamics within the market. ## **US Gene Therapy Market Segmentation Insights** ### **Gene Therapy Market Therapeutic Area Outlook** ### **Gene Therapy Market Technology Outlook** ### **Gene Therapy Market Application Outlook** ### **Gene Therapy Market Route of Administration Outlook** ## Market Drivers ### Growing Awareness and Acceptance Public awareness and acceptance of gene therapy are on the rise, contributing positively to the gene therapy market. Educational campaigns and success stories of patients benefiting from gene therapies are helping to demystify these treatments. Surveys indicate that over 70% of the US population is now aware of gene therapy and its potential benefits. This growing acceptance is likely to lead to increased demand for gene therapies, as patients and healthcare providers become more open to exploring these innovative options. The gene therapy market stands to gain from this shift in perception, as it encourages investment and research into new therapeutic avenues. ### Increased Funding and Investment The gene therapy market is experiencing a surge in funding and investment from both public and private sectors. Venture capital investments in biotech firms focused on gene therapy have increased significantly, with estimates suggesting a rise of over 30% in the last few years. This influx of capital is facilitating the development of new therapies and accelerating clinical trials. Additionally, government initiatives aimed at promoting biotechnology research are further bolstering the market. The gene therapy market is thus likely to see a proliferation of novel therapies entering the market, driven by this financial support and the urgency to address unmet medical needs. ### Rising Prevalence of Genetic Disorders The increasing incidence of genetic disorders in the US is a primary driver for the gene therapy market. Conditions such as cystic fibrosis, hemophilia, and muscular dystrophy are becoming more prevalent, necessitating innovative treatment options. According to the National Institutes of Health, approximately 1 in 10 individuals in the US is affected by a genetic disorder, which translates to millions of potential patients. This growing patient population is likely to stimulate demand for gene therapies, as they offer the potential for curative treatments rather than lifelong management. The gene therapy market is thus positioned to expand significantly as healthcare providers seek effective solutions to address these complex conditions. ### Advancements in Gene Editing Technologies Recent breakthroughs in gene editing technologies, particularly CRISPR and TALEN, are propelling the gene therapy market forward. These technologies enable precise modifications to the genome, allowing for targeted therapies that can correct genetic defects at their source. The market for gene editing is projected to reach $10 billion by 2026, indicating robust growth potential. As these technologies become more refined and accessible, they are likely to enhance the efficacy and safety of gene therapies. Consequently, the gene therapy market is expected to benefit from the integration of these advanced techniques, leading to innovative treatment options that could transform patient outcomes. ### Regulatory Support and Streamlined Approval Processes The regulatory landscape for gene therapies in the US is evolving, with agencies like the FDA implementing more streamlined approval processes. This regulatory support is crucial for the gene therapy market, as it reduces the time and cost associated with bringing new therapies to market. The FDA has introduced initiatives such as the Regenerative Medicine Advanced Therapy designation, which expedites the review of promising gene therapies. As a result, the gene therapy market is likely to see an increase in the number of approved therapies, fostering innovation and competition within the sector. ## Future Outlook The [Gene Therapy Market](https://www.marketresearchfuture.com/reports/gene-therapy-market-8399) is projected to grow at a 17.84% CAGR from 2025 to 2035, driven by advancements in technology, regulatory support, and increasing disease prevalence. **New opportunities:** - Development of personalized gene therapies for rare diseases - - Expansion of telehealth services for remote patient monitoring - Investment in scalable manufacturing technologies for cost reduction By 2035, the gene therapy market is expected to achieve substantial growth and innovation. ## Segment Insights ### By Vector Type: Viral Vector (Largest) vs. Non-Viral Vector (Fastest-Growing) In the US gene therapy market, the distribution of vector types is predominantly led by viral vectors, which hold a significant share owing to their proven efficacy and efficiency in gene delivery. This segment benefits from a robust pipeline of products, boosted by advancements in vector engineering and regulatory approvals that facilitate their use in therapeutic applications. On the other hand, non-viral vectors are emerging as the fastest-growing segment, driven by innovations in technology and increasing investments in research and development. Their appeal lies in lower immunogenicity, safety, and flexibility in manufacturing. With rising demand for gene therapies targeted at genetic disorders and cancer treatments, non-viral vectors are positioned for accelerated growth in the coming years. Vector Type: Viral Vector (Dominant) vs. Non-Viral Vector (Emerging) Viral vectors have established themselves as the dominant force in the US gene therapy market due to their high transduction efficiency and reliability in delivering therapeutic genes to target cells. These vectors, including Lentivirus and Adenovirus, are extensively used in clinical settings for a variety of applications. Conversely, non-viral vectors, such as plasmids and liposomes, represent an emerging market segment, gaining traction for their safety profile and ease of production. They present unique advantages like reduced risk of infection and the ability to deliver larger DNA sequences, making them attractive for applications such as CRISPR gene editing. The shift towards non-viral methods reflects a broader trend towards personalized medicine, with particular focus on innovative and safe therapeutic options. ### By Gene Type: Cytokine (Largest) vs. Antigen (Fastest-Growing) In the US gene therapy market, the 'Gene Type' segment exhibits a diverse distribution of market share. Cytokines are at the forefront, commanding the largest share, attributed to their essential role in immune modulation and their established efficacy in various therapeutic applications. Antigens are emerging rapidly, fueled by advancements in targeted therapies and precision medicine, indicating a significant shift in treatment paradigms. Growth trends within this segment are predominantly driven by innovations in genetic modulation techniques, alongside increasing investments in research and development. The rise of personalized medicine is propelling the adoption of antigen-based therapies, while cytokines remain pivotal for their proven track record in treating chronic diseases. This dynamic landscape presents opportunities for both established and emerging gene types to thrive in the market. Cytokine (Dominant) vs. Antigen (Emerging) Cytokines have established themselves as a dominant force in the US gene therapy market due to their versatile applications in immune response modulation. They play critical roles in various therapeutic strategies, particularly for autoimmune diseases and cancer treatments. Their effectiveness and the growth of related clinical trials solidify their market position. Conversely, antigens are poised as an emerging segment, driven by the advancements in targeted and personalized therapies. Their adoption is spurred by the increasing need for specificity in treatment, which aligns with current healthcare trends towards individualized patient care. As R&D in this area expands, antigens are expected to carve out a substantial niche, catering to the evolving demands of modern therapeutics. ### By Application: Oncological Disorders (Largest) vs. Rare Diseases (Fastest-Growing) The US gene therapy market exhibits a diverse application landscape, with oncological disorders commanding the largest market share. This segment is pivotal due to the increasing incidence of various cancers and the growing adoption of innovative gene therapies aimed at treating these conditions. Following closely, rare diseases represent an emerging opportunity in the market, driven by advancements in genomic medicine and a heightened focus on personalized therapies for previously underserved populations. The growth trends in this market are significantly influenced by improved research and development in gene therapies, regulatory support, and rising collaborations between biotech firms and academic institutions. Particularly, oncological disorders are expected to benefit from ongoing clinical trials and treatment innovations. In contrast, the rare diseases segment is experiencing rapid advancements due to increased funding and patient advocacy, positioning it as the fastest-growing area within the applications of gene therapy. Oncological Disorders (Dominant) vs. Rare Diseases (Emerging) Oncological disorders represent the dominant application within the US gene therapy market, characterized by a robust pipeline of therapies aimed at tackling various types of cancers. These treatments often harness cutting-edge technologies, including CRISPR and viral vectors, to provide targeted interventions. The effectiveness of gene therapies is enhanced by the growing understanding of the genetic underpinnings of cancer, leading to personalized treatment strategies that significantly improve patient outcomes. Conversely, the rare diseases segment is emerging as a crucial focus for many biotech firms, driven by the need for tailored therapies for patients with genetic disorders. This sector is increasingly recognized for its potential due to favorable regulatory environments and incentives, fueling innovation and investment in this area. ### By Delivery Method: In Vivo Gene Therapy (Largest) vs. Ex Vivo Gene Therapy (Fastest-Growing) The US gene therapy market exhibits clear distinctions in market share across the delivery methods. Currently, In Vivo Gene Therapy leads the segment with substantial market share, primarily due to its innovative approach of directly delivering genetic material into the patient's body. Conversely, Ex Vivo Gene Therapy, while holding a smaller share, is experiencing rapid growth as more therapies are being developed and approved, focusing on specific treatment methodologies. Growth trends in the delivery method segment are heavily influenced by advancements in technology and increased pipeline activities. The increasing prevalence of genetic disorders and the push for personalized treatment solutions are driving the demand for both segments. Ex Vivo Gene Therapy is becoming increasingly significant due to its precision-targeting capabilities, leading to a surge in investment and research into this delivery method, making it the fastest-growing segment. Delivery Method: In Vivo Gene Therapy (Dominant) vs. Ex Vivo Gene Therapy (Emerging) In Vivo Gene Therapy is characterized by its dominant position, employing techniques that involve the direct injection of therapeutic genes into tissues, allowing for efficient absorption and action within the target areas. This method leverages advancements in vectors and has proven effective in treating various genetic disorders. On the other hand, Ex Vivo Gene Therapy, while currently emerging, focuses on modifying cells outside the body before reintroducing them. This approach is particularly advantageous due to its ability to enhance selectivity and minimize off-target effects, making it appealing in the therapeutic landscape. The growth in Ex Vivo Gene Therapy is propelled by ongoing research and regulatory approvals, as it presents a promising avenue for treating complex genetic conditions. ## Competitive Benchmarking The [gene therapy market](https://www.marketresearchfuture.com/reports/gene-therapy-market-8399) is currently characterized by a dynamic competitive landscape, driven by rapid advancements in technology and increasing investment in research and development. Major players such as Novartis (CH), Gilead Sciences (US), and Bluebird Bio (US) are strategically positioning themselves through innovation and partnerships. Novartis (CH) has focused on expanding its portfolio of gene therapies, particularly in the treatment of rare diseases, while Gilead Sciences (US) emphasizes its commitment to developing transformative therapies for patients with serious conditions. Bluebird Bio (US) is concentrating on its gene therapy pipeline, particularly in the area of genetic disorders, which collectively shapes a competitive environment that is increasingly reliant on cutting-edge research and collaborative efforts.Key business tactics within this market include localizing manufacturing and optimizing supply chains to enhance efficiency and reduce costs. The competitive structure appears moderately fragmented, with several key players exerting influence over various segments. This fragmentation allows for a diverse range of therapeutic options, although it also necessitates strategic collaborations among companies to leverage complementary strengths and capabilities. In October Novartis (CH) announced a strategic partnership with a leading biotechnology firm to co-develop a novel gene therapy targeting a rare genetic disorder. This collaboration is expected to accelerate the development timeline and enhance the therapeutic potential of the treatment, reflecting Novartis's commitment to innovation and its proactive approach to addressing unmet medical needs. Such partnerships are likely to bolster Novartis's competitive position in the market. In September Gilead Sciences (US) launched a new gene therapy aimed at treating a specific type of inherited retinal disease. This launch not only underscores Gilead's focus on expanding its gene therapy portfolio but also highlights its strategy of addressing niche markets with high unmet needs. The introduction of this therapy may enhance Gilead's reputation as a leader in innovative treatments, potentially attracting further investment and interest from stakeholders. In August Bluebird Bio (US) secured a significant funding round to advance its gene therapy programs, particularly those targeting beta-thalassemia and sickle cell disease. This influx of capital is crucial for Bluebird's ongoing research and development efforts, allowing the company to maintain its competitive edge in the rapidly evolving gene therapy landscape. The funding is indicative of investor confidence in Bluebird's strategic direction and its potential to deliver impactful therapies. As of November current trends in the gene therapy market include a pronounced shift towards digitalization, sustainability, and the integration of artificial intelligence in research and development processes. Strategic alliances are increasingly shaping the competitive landscape, enabling companies to pool resources and expertise. Looking ahead, competitive differentiation is likely to evolve, with a greater emphasis on innovation and technology rather than solely on price. The reliability of supply chains will also play a critical role in determining market success, as companies strive to deliver effective therapies in a timely manner. ## Recent News & Developments Recent months have seen significant developments in the US Gene Therapy Market. Novartis received FDA approval for its gene therapy treatment Zolgensma for spinal muscular atrophy in July 2023, marking a pivotal moment in the treatment landscape. In September 2023, Gilead Sciences announced positive trial results for its gene therapy targeting hemophilia, showcasing advancements in therapeutic applications. Mergers and acquisitions maintain momentum, with Amgen acquiring Five Prime Therapeutics in May 2023 to augment its oncology portfolio, with implications for gene therapy advancements in cancer treatment. In terms of market valuation, companies like Bluebird Bio have experienced volatility, significantly impacting investor confidence and overall market stability. Current affairs indicate that regulatory frameworks are evolving to accommodate rapid advancements in gene therapy, driven by the FDA's commitment to expedite both approvals and patient access to innovative treatments, reflecting a broader trend in personalized medicine. Major happenings over the last few years underscore the urgency for continued investment in Research and Development, with CRISPR Therapeutics making strides in gene editing technology, further enhancing competitive dynamics within the market. ## Report Scope | MARKET SIZE 2024 | 1150.0(USD Million) | | --- | --- | | MARKET SIZE 2025 | 1355.16(USD Million) | | MARKET SIZE 2035 | 7000.0(USD Million) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 17.84% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Million | | Key Companies Profiled | Novartis (CH), Gilead Sciences (US), Sangamo Therapeutics (US), Bluebird Bio (US), Spark Therapeutics (US), CRISPR Therapeutics (CH), Bristol-Myers Squibb (US), Roche (CH), AstraZeneca (GB), Regeneron Pharmaceuticals (US) | | Segments Covered | Vector Type, Gene Type, Application, Delivery Method | | Key Market Opportunities | Advancements in gene editing technologies enhance treatment options in the gene therapy market. | | Key Market Dynamics | Regulatory advancements and technological innovations drive growth in the gene therapy market, enhancing treatment accessibility and efficacy. | | Countries Covered | US | ## Frequently Asked Questions **Q: What was the market valuation of the US gene therapy market in 2024?** A: The market valuation of the US gene therapy market was $1150.0 Million in 2024. **Q: What is the projected market valuation for the US gene therapy market by 2035?** A: The projected market valuation for the US gene therapy market is $7000.0 Million by 2035. **Q: What is the expected CAGR for the US gene therapy market during the forecast period 2025 - 2035?** A: The expected CAGR for the US gene therapy market during the forecast period 2025 - 2035 is 17.84%. **Q: Which companies are considered key players in the US gene therapy market?** A: Key players in the US gene therapy market include Novartis, Gilead Sciences, Sangamo Therapeutics, Bluebird Bio, Spark Therapeutics, CRISPR Therapeutics, Bristol-Myers Squibb, Roche, AstraZeneca, and Regeneron Pharmaceuticals. **Q: What are the two main types of vectors used in gene therapy, and what were their valuations in 2024?** A: In 2024, the valuations for viral vectors and non-viral vectors were $800.0 Million and $350.0 Million, respectively. **Q: What types of gene therapies are included in the market, and what were their valuations in 2024?** A: In 2024, the valuations for various gene types included Antigen at $1150.0 Million, while Cytokine, Tumor Suppressor, Suicide, Deficiency, Growth Factors, Receptors, and Others were each valued at $115.0 Million. **Q: What applications are driving the US gene therapy market, and what were their valuations in 2024?** A: In 2024, the applications driving the market included Rare Diseases at $400.0 Million, Oncological Disorders at $230.0 Million, and Neurological Disorders at $200.0 Million. **Q: What delivery methods are utilized in gene therapy, and what were their valuations in 2024?** A: In 2024, In Vivo Gene Therapy was valued at $690.0 Million, while Ex Vivo Gene Therapy was valued at $460.0 Million. **Q: How does the market for rare diseases compare to other applications in the US gene therapy market?** A: The market for rare diseases, valued at $400.0 Million in 2024, appears to be one of the leading applications, surpassing Oncological Disorders and Neurological Disorders. **Q: What trends are anticipated in the US gene therapy market as it approaches 2035?** A: As the US gene therapy market approaches 2035, it is likely to experience substantial growth, potentially reaching a valuation of $7000.0 Million, driven by advancements in technology and increased investment. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/us-gene-therapy-market-14614*